News
KRYS
371.58
-0.02%
-0.09
FDA PreCheck Could Speed Up These 3 U.S. Biopharma Stocks
Simply Wall St · 2d ago
Weekly Report: what happened at KRYS last week (0622-0626)?
Weekly Report · 3d ago
Krystal Biotech EVP, General Counsel John C. Thomas disposes of USD 347,270 in common shares
PUBT · 5d ago
Krystal Biotech (KRYS) Rallies On Pipeline Optimism, Is The Stock Already Pricey?
Simply Wall St · 6d ago
10 large and mega-cap U.S. healthcare stocks with the strongest momentum grades
Seeking Alpha · 06/24 13:35
Krystal Biotech (KRYS) Is Up 7.2% After Institutional Ownership Surges To Sector-Leading Levels
Simply Wall St · 06/22 18:27
As AbbVie eyes Apogee, these biotech stocks earn the highest Quant ratings
Seeking Alpha · 06/22 13:32
Weekly Report: what happened at KRYS last week (0615-0619)?
Weekly Report · 06/22 10:21
Krystal Biotech (KRYS) Revenue Growth Puts VYJUVEK Pipeline Progress In Focus
Simply Wall St · 06/18 23:50
Krystal Biotech Is Maintained at Buy by TD Cowen
Dow Jones · 06/18 14:42
TD Cowen Maintains Buy on Krystal Biotech, Raises Price Target to $403
Benzinga · 06/18 14:33
Krystal Biotech price target raised to $403 from $306 at TD Cowen
TipRanks · 06/18 12:00
KRYSTAL BIOTECH INC <KRYS.O>: TD COWEN RAISES TARGET PRICE TO $403 FROM $306
Reuters · 06/18 10:46
Analysts Are Bullish on These Healthcare Stocks: BrightSpring Health Services, Inc. (BTSG), Relay Therapeutics (RLAY)
TipRanks · 06/18 09:51
These 3 Stocks Have Crushed the Market This Year. Here's Why There Is More Upside Ahead
The Motley Fool · 06/18 05:50
Krystal Biotech Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 06/16 15:53
Krystal Biotech Price Target Raised to $361.00/Share From $310.00 by HC Wainwright & Co.
Dow Jones · 06/16 15:53
HC Wainwright & Co. Maintains Buy on Krystal Biotech, Raises Price Target to $361
Benzinga · 06/16 15:44
Krystal Biotech price target raised to $361 from $310 at H.C. Wainwright
TipRanks · 06/16 13:08
KRYSTAL BIOTECH, INC. <KRYS.O>: H.C. WAINWRIGHT RAISES TARGET PRICE TO $361 FROM $310
Reuters · 06/16 13:01
More
Webull provides a variety of real-time KRYS stock news. You can receive the latest news about Krystal Biotech through multiple platforms. This information may help you make smarter investment decisions.
About KRYS
Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. The Company is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include KB407, KB408, KB707, KB105, KB801, KB803, KB304 and KB301. Its commercial product, VYJUVEK, is a redosable gene therapy, and a genetic medicine approved in the United States and Europe for the treatment of dystrophic epidermolysis bullosa. KB407 is being developed for the treatment of Cystic Fibrosis. KB408 is being developed for the treatment of Alpha-1 Antitrypsin Deficiency, a rare lung disease. KB707 is being developed for the treatment of solid tumors. KB105 is being developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis. KB803 is a redosable eye drop formulation of B-VEC, designed for the treatment of ocular complications.